RECURSION PHARMACEUTICALS, INC. Impairment of Leasehold
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Impairment of Leasehold of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLeasehold · last filed 2025-02-28
- RECURSION PHARMACEUTICALS, INC. impairment of leasehold for the quarter ending 2024-09-30 was $0.00.
- RECURSION PHARMACEUTICALS, INC. impairment of leasehold for the quarter ending 2024-06-30 was $0.00.
- RECURSION PHARMACEUTICALS, INC. impairment of leasehold for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. impairment of leasehold for the quarter ending 2023-12-31 was $0.00.
- RECURSION PHARMACEUTICALS, INC. impairment of leasehold for fiscal 2023 was $1.20M, a 57.14% decline from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. impairment of leasehold for fiscal 2022 was $2.80M.
| Period end | Impairment of Leasehold 3 month | Impairment of Leasehold 6 month | Impairment of Leasehold 9 month | Impairment of Leasehold 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-02-28 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-02-28 | $0.00 derived: sum of 4 quarters · filed 2025-02-28 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 derived: sum of 3 quarters · filed 2025-02-28 | $0.00 derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 derived: sum of 3 quarters · filed 2025-02-28 | $1.20M 10-K · filed 2025-02-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $1.20M 10-Q · filed 2024-11-06 | $1.20M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.20M 10-Q · filed 2024-08-08 | $1.20M derived: sum of 3 quarters · filed 2024-08-08 | $1.20M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.20M 10-Q · filed 2024-05-09 | $1.20M derived: sum of 2 quarters · filed 2024-05-09 | $1.20M derived: sum of 3 quarters · filed 2024-05-09 | $4.00M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $2.80M derived: sum of 3 quarters · filed 2024-02-29 | $2.80M 10-K · filed 2024-02-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.80M derived: sum of 2 quarters · filed 2022-11-08 | $2.80M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $2.80M 10-Q · filed 2022-08-09 | $2.80M 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |